PI3K pathway inhibitors approach junction

Abstract

False starts As with many drug targets, the development of PI3K inhibitors has been beset by false starts. In 1993 the first pan-PI3K inhibitor — the naturally occurring bacterial product wortmannin — was discovered. It was quickly followed by Lilly’s LY294002, a morpholino derivative of the broad-spectrum kinase inhibitor quercetin. Although these… (More)
DOI: 10.1038/nrd3527

Topics

2 Figures and Tables